News

“Cosmopolitanism and curiosity about all things new form the fundamental values of every university,” emphasised FAU President Prof. Dr. Joachim Hornegger in July 2015. With this in mind, FAU is taking part in the initiative “Weltoffene Hochschule” (Open-minded University) of the German Rectors’ Conference (HRK).

Climate change is progressing rapidly. It is not the first time in our planet's history that temperatures have been rising, but it is happening much faster now than it ever has before. Or is it? Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have shown in the latest edition o...

Pain research faces a significant challenge: there is a lack of research into suitable human pain-sensing nerve cells. Researchers at FAU have now discovered a way of using human stem cell technology to carry out more effective research into pain in humans.

RRZE's new free data storage service synchronises files via desktop, app or browser

Researchers have developed a new technology that makes understanding easier

The humanities at FAU have been rated highly by the THE Subject Ranking, as FAU is ranked at number 79 in the world and number 9 in Germany in the subject category Arts and Humanities. The University has also risen up the ranks in the U.S. News ranking.

On 4 November 2015, the President of Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Prof. Dr. Joachim Hornegger, invited guests to celebrate the 272nd anniversary of the University’s foundation. The title of FAU Ambassador was awarded for the first time.

Developments in medicine and society are just some of the factors that have caused changes to how we deal with death and dying. What does dying with dignity look like today? What conditions are required in hospice and palliative care?

We would like to thank all of the helpers, institutes, chairs and departments that took part in the Long Night of Sciences.

At FAU, researchers at the Institute of Clinical and Molecular Virology at Universitätsklinikum Erlangen are working on a new HIV vaccination strategy that makes use of the immune response to a hepatitis B vaccine that has already been approved.